InvestorsHub Logo

rafunrafun

04/06/16 1:56 PM

#76957 RE: amarininvestor #76956

That's over 29 months, which equals to approximately 5.0% annual rate.

HDGabor

04/06/16 4:44 PM

#76989 RE: amarininvestor #76956

a- (& centurycom #76967)

I leave it for more science educated posters, but my quick take away:

- it was 10 years ago
- in Korea (!!!)
- Limitations of this study include weak statistical power due to the small patient group and the low event rate [The 12.6% was a yearly event rate since the study - follow-up - was 12-month for each patient]

What are the chances that the rate in R-IT is actually much larger than 5.9%?

We have a good chance. The extra 1,000 patients allow (but does not predict) lower (5.2%) rate than 5.9%. pre-SPA 5.9% means, they expected more.

- - - - -
centurycom #76967

If you mean "1,050 or 1,100": these were just for example
if you mean "more than 967": The combination of the many CV events which have been adjudicated together with the CV events pending adjudicated. Adjudication is starting after occurrence.

- - - - -

Best,
G

Whalatane

04/06/16 5:08 PM

#76993 RE: amarininvestor #76956

Am thx for the link

My quick take ...this study measured the "on treatment " effect of the statins on ALL the trial participants . There was no "placebo " group.
These patients underwent PCI and were started on Satin therapy before discharge .

This group was also very high risk
Before discharge and at start of therapy
98.6 % now with drug eluting stents
87.3 % on ACE /ARD
HsCRP over 4 at start of therapy.
etc

My read is that these patients were NOT on statins before starting the trial where as in RI I believe all were .
Just my quick take
Kiwi